NDA 215039 · Novartis
Vijoice
Alpelisib · Oral
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jul 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Apr 5, 2022
Approved uses
2
Original approval plus efficacy supplements
Registered trials
109
10 Phase 3, 22 recruiting
FAERS reports
1,873
1,427 serious, 236 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 27, 2026.
VIJOICE is indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). VIJOICE is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )
Mechanism: Alpelisib is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3Kα. Gain-of-function mutations in the gene encoding the catalytic α-subunit of PI3K (PIK3CA) lead to activation of PI3Kα and Akt-signaling, cellular transformation and the generation of tumors in in vitro and in vivo models. Activating mutations in PIK3CA have been found to induce a spectrum of overgrowths and malformations comprising a wide group of clinically recognizable disorders commonly known as PROS. In an inducible mouse model of Congenital Lipomatous Overgrowth,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 24, 2024 Supplement 2 · Efficacy OrphanLetter
- Apr 5, 2022 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated · priority review NovelBreakthrough therapyAccelerated approvalOrphanLetterLabelReview
3 products under this application
- VIJOICE · ALPELISIB 200MG · TABLET, ORAL · Prescription
- VIJOICE · ALPELISIB 50MG · TABLET, ORAL · Prescription
- VIJOICE · ALPELISIB 125MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Alpelisib" as an intervention, any sponsor and status, largest first.
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05564377 · 2,900 participants (planned) · Start Apr 7, 2023 · Primary completion Jul 1, 2030
Drug: Alpelisib; Binimetinib and 13 more · For: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 and 12 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 484 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT05768139 · 880 participants (planned) · Start Apr 17, 2023 · Primary completion Jul 2030
Drug: STX-478; Fulvestrant and 9 more · For: Breast Cancer; Solid Tumors, Adult
Sites: Los Angeles, California; San Francisco, California; Aurora, Colorado · 65 sites in all
- Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)Pivotal-lookingActive, not recruiting
Celcuity IncIndustry
NCT05501886 · 701 participants (planned) · Start Dec 8, 2022 · Primary completion Jun 30, 2026
Drug: Gedatolisib; Palbociclib and 2 more · For: Breast Cancer
Sites: Birmingham, Alabama; Goodyear, Arizona; Jonesboro, Arkansas · 235 sites in all
- Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02437318 · 572 participants · Start Jul 23, 2015 · Primary completion Jun 12, 2018
Drug: Fulvestrant; Alpelisib and 1 more · For: Breast Cancer
Sites: Chandler, Arizona; Scottsdale, Arizona; Fayetteville, Arkansas · 197 sites in all
- Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerActive, not recruiting
Stemline Therapeutics, Inc.Industry
NCT05563220 · 435 participants (planned) · Start Jan 24, 2023 · Primary completion Dec 27, 2026
Drug: Elacestrant; Alpelisib and 5 more · For: Breast Cancer; Metastatic Breast Cancer
Sites: Dothan, Alabama; Phoenix, Arizona; Springdale, Arkansas · 83 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05646862 · 420 participants (planned) · Start Jun 7, 2023 · Primary completion Nov 13, 2026
Drug: Inavolisib; Fulvestrant and 4 more · For: Breast Cancer
Sites: Greenbrae, California; Los Alamitos, California; Los Angeles, California · 210 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hyperglycaemia351
- malignant neoplasm progression249
- rash210
- diarrhoea205
- fatigue127
- drug ineffective124
- nausea123
- breast cancer metastatic117
- death117
- metastases to bone94
- blood glucose increased92
- weight decreased91
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 90 |
| 2020 | 172 |
| 2021 | 269 |
| 2022 | 402 |
| 2023 | 334 |
| 2024 | 228 |
| 2025 | 192 |
| 2026 | 177 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vijoice (Alpelisib)
2024 spending
$8.5M
Beneficiaries
42
214 claims
Per beneficiary
$203,257
$979.44 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $1,894,697 |
| 2023 | $5,958,633 |
| 2024 | $8,536,782 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
André F, Ciruelos E, Rubovszky G, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
- Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
André F, Ciruelos EM, Juric D, et al. · Ann Oncol 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors.
Pathak N, Mittal A, Kumar S, et al. · Curr Oncol 2025 · Network Meta-Analysis, Systematic Review
- Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.
Henry NL, Somerfield MR, Dayao Z, et al. · J Clin Oncol 2022 · Systematic Review, Practice Guideline
- Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Rugo HS, Lerebours F, Ciruelos E, et al. · Lancet Oncol 2024 · Multicenter Study, Clinical Trial, Phase II
- Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
Burstein HJ, Somerfield MR, Barton DL, et al. · J Clin Oncol 2021 · Systematic Review
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.